

03 MAY 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



534066


(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/041249 A1

- (51) International Patent Classification⁷: **A61K 9/107**
- (21) International Application Number:
PCT/KR2003/002388
- (22) International Filing Date:
7 November 2003 (07.11.2003)
- (25) Filing Language: Korean
- (26) Publication Language: English
- (30) Priority Data:
10-2002-0069222
8 November 2002 (08.11.2002) KR
- (71) Applicant (for all designated States except US): **HANMI PHARM. CO., LTD.** [KR/KR]; #893-5, Hajeo-ri, Paltan-myeon, Hwaseong-gun, Kyungki-do 445-910 (KR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **WOO, Jong Soo** [KR/KR]; Baekseolmaeul 598-1302, Jeongja-dong, Jang-gan-gu, Suwon-si, Kyungki-do, Kyungki-do 440-300 (KR). **KIM, Ae Guk** [KR/KR]; Jinju Apt. 305-905, Kajwa-2-dong, Seo-gu, Incheon 404-762 (KR).
- (74) Agent: **JANG, Seongku**; 19th Fl., KEC Building, #275-7., Yangjae-dong, Seocho-ku, Seoul 137-130 (KR).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MICROEMULSION CONCENTRATE FOR ORAL ADMINISTRATION OF WATER-INSOLUBLE ANTI-COLD DRUG AND METHOD FOR PREPARING SAME



(57) Abstract: A microemulsion concentrate comprising a water-insoluble anti-cold drug, a surfactant and an oil, which is prepared by a method comprising: (a) dissolving the water-insoluble anti-cold drug in a co-surfactant to obtain a homogeneous drug solution; (b) adding the surfactant and the oil in the drug solution to obtain a microemulsion pre-concentrate; and (c) removing the co-surfactant from the pre-concentrate, contains emulsified drug microparticles which are stable toward pH change and therefore, provides improved bioavailability of the drug when orally administered.

WO 2004/041249 A1

**MICROEMULSION CONCENTRATE FOR ORAL ADMINISTRATION
OF WATER-INSOLUBLE ANTI-COLD DRUG AND METHOD FOR
PREPARING SAME**

5 **FIELD OF THE INVENTION**

The present invention relates to a microemulsion concentrate for oral administration of a water-insoluble anti-cold drug, which provides an improved bioavailability of the drug, and a method for preparing same. More particularly,
10 it pertains to a microemulsion concentrate comprising a water-insoluble anti-cold drug, a surfactant and an oil, and a method for the preparation thereof comprising the steps of (a) dissolving the water-insoluble anti-cold drug in a co-surfactant to obtain a homogeneous drug solution; (b) adding the surfactant and the oil in the drug solution to obtain a microemulsion pre-concentrate; and (c) removing the co-
15 surfactant from the pre-concentrate.

BACKGROUND OF THE INVENTION

As an active ingredient of an anti-cold drug for relieving the symptoms of a
20 cold such as fever, pain, inflammation and cough, various compounds including acetaminophen, ibuprofen, dextromethorphan hydrobromide, noscapine hydrochloride, trimetoquinol hydrochloride, guaifenesin, d-chlorpheniramine maleate, carbetapentane citrate, tipecidine citrate, cloperastine hydrochloride, cloperastine fendizoate, tipecidine hibenzate, d,l-methylephedrine hydrochloride,
25 ephedrine hydrochloride, phenylephedrine hydrochloride, pseudoephedrine hydrochloride, phenylpropanolamine, diphexamide, phenylaminopropanol hydrochloride, oxymetazoline, xylometazoline and the like are currently used.

However, these compounds are practically insoluble in water and, therefore, they exhibit a low absorption rate and bioavailability when orally administered in
30 the form of a solid formulation such as a tablet or a capsule. Further, a syrup formulation containing such compounds is not preferred due to its bulkiness.

Accordingly, there have been reported a number of methods to make a soft-capsule containing a high-concentrate of these compounds to improve the absorption rate and bioavailability thereof.

For example, Korean Patent Laid-open, Publication No. 1996-7003576
5 (Publication Date: 1996. 8. 31) discloses a soft capsule of acetaminophen comprising acetaminophen; polyethyleneglycol, propyleneglycol and water as solvents; an alkali metal acetate as an alkalizer for improving the solubility of the drug; and polyvinylpyrrolidone as a polymer for preventing precipitation. Korean Patent Laid-open Publication No. 2000-31737 (Publication Date: 2000. 6. 5) discloses a
10 soft capsule of acetaminophen comprising acetaminophen; PEG-8-glyceryl caprylate/caprate, diethyleneglycol monoethylether and polyethyleneglycol as solvents; and polyvinylpyrrolidone as a polymer for preventing precipitation. Further, Korean Patent Laid-open Publication No. 1999-11219 (Publication Date: 1999. 2. 18) discloses a soft capsule comprising a drug, polyethyleneglycol, a non-
15 ionic surfactant, a stabilizer, glycerin, water and polyvinylpyrrolidone.

On the other hand, Korean Patent Laid-open Publication No. 1997-9793 (Publication Date: 1997. 3. 27) discloses a method for preparing a liquid formulation of ibuprofen comprising dissolving ibuprofen in a mixture of polyoxyethylenesorbitan fatty acid ester, polyglycerin fatty acid ester and water,
20 adding polyvinylpyrrolidone thereto, and heating the resulting mixture to about 80°C. Korean Patent Laid-open Publication No. 1998-73629 (Publication Date: 1998. 11. 5) discloses a method for preparing a liquid formulation of ibuprofen comprising mixing ibuprofen, polyethyleneglycol, a surfactant and polyvinylpyrrolidone and heating the resulting mixture.

25 However, the above high-concentrate liquid formulations, which are prepared by simple solubilization of the anti-cold drug would fail to provide a desired absorption rate and bioavailability due to the possible precipitation of the drug upon contact with an aqueous body fluid. Further, the absorbability of the drug may exhibit a significant individual variation.

30 Accordingly, the inventors have endeavoured to develop a drug delivery

system for enhancing the bioavailability of a sparingly water-soluble drug.

SUMMARY OF THE INVENTION

5 Accordingly, it is an object of the present invention to provide a method for preparing a microemulsion concentrate for oral administration of a water-insoluble anti-cold drug.

 It is another object of the present invention to provide a microemulsion concentrate for oral administration of a water-insoluble anti-cold drug prepared by
10 the above method.

BRIEF DESCRIPTION OF THE DRAWINGS

 The above and other objects and features of the present invention will
15 become apparent from the following description of the invention, when taken in conjunction with the accompanying drawings, in which:

 Fig. 1 displays the dissolution rates of the inventive ibuprofen preparation of Example 1 and a commercially available ibuprofen preparation (Brufen[®] tab.) (Fig. 1a: artificial gastric juice, Fig. 1b: water).

20 Fig. 2 displays the particle size distribution of the emulsified microparticles formed from the inventive ibuprofen preparation of Example 1 upon contact with an aqueous solution.

 Fig. 3 shows the bioavailabilities of the inventive ibuprofen preparation of Example 1 and a commercially available ibuprofen preparation (Brufen[®] tab.).

25

DETAILED DESCRIPTION OF THE INVENTION

 In accordance with one aspect of the present invention, there is provided a method for preparing a microemulsion concentrate for oral administration of a
30 water-insoluble anti-cold drug comprising (a) dissolving the water-insoluble anti-

cold drug in a co-surfactant to obtain a homogeneous drug solution; (b) adding a surfactant and an oil in the drug solution to obtain a microemulsion pre-concentrate; and (c) removing the co-surfactant from the pre-concentrate.

In accordance with another aspect of the present invention, there is
5 provided an oral microemulsion concentrate comprising a water-insoluble anti-cold drug, a surfactant and an oil.

The microemulsion concentrate of the present invention is characterized by not containing a co-surfactant therein.

According to the present invention, a microemulsion concentrate
10 comprising a water-insoluble anti-cold drug, a surfactant and an oil is prepared by a method comprising (a) dissolving the water-insoluble anti-cold drug in a co-surfactant to obtain a homogeneous drug solution; (b) adding the surfactant and the oil in the drug solution to obtain a microemulsion pre-concentrate; and (c)
15 heating the microemulsion pre-concentrate at a temperature above the boiling point of the co-surfactant, preferably, at a temperature ranging from 50 to 100 °C, till the co-surfactant is sufficiently volatilized, preferably, more than 4 hours to remove the co-surfactant from the pre-concentrate.

The respective components employed for the preparation of the inventive microemulsion concentrate are described in detail as follows.

20

(1) Active ingredient

As an active ingredient, any one of known water-insoluble anti-cold drugs can be used. For instance, it may be selected from the group consisting of acetaminophen, ibuprofen, S-ibuprofen, dextromethorphan hydrobromide,
25 noscapine hydrochloride, trimetoquinol hydrochloride, guaifenesin, d-chlorpheniramine maleate, carbapentane citrate, tipecidine citrate, cloperastine hydrochloride, cloperastine fendizoate, tipecidine hibenzate, d,l-methylephedrine hydrochloride, ephedrine hydrochloride, phenylephedrine hydrochloride, pseudoephedrine hydrochloride, phenylpropanolamine and a mixture thereof.

30

(2) Co-surfactant

In the present invention, the co-surfactant serves to dissolve the water-insoluble anti-cold drugs (active ingredient) and facilitates the preparation process by decreasing the viscosity of the reaction mixtures, however, is not contained in the finally obtained microemulsion concentrate. The co-surfactant preferably has a boiling point below 100 °C so that it volatilizes easily. Representative examples thereof include alcohols, acetic acid, lactic acid, glycerin, propyleneglycol, acetone, methylene chloride and the like, wherein alcohols, acetic acid, lactic acid, glycerin and propyleneglycol are more preferable since they are non-toxic to human body, and ethanol is most preferable.

(3) Surfactant

The surfactant for use in the present invention may be any one of the pharmaceutically acceptable surfactants, which stably emulsifies an oil and hydrophilic ingredients such as the co-surfactant in water. Representative examples of the surfactant include:

- ① polyoxyethylene glycolated natural or hydrogenated vegetable oils such as polyoxyethylene glycolated natural or hydrogenated castor oil(Cremophor[®], BASF; and HCO[®], Nikkol),
- ② polyoxyethylene-sorbitan-fatty acid esters wherein fatty acid is mono- or tri-lauric, palmitic, stearic or oleic acid(Tween[®], ICI),
- ③ polyoxyethylene fatty acid esters such as polyoxyethylene stearic acid ester(Myrij[®], ICI),
- ④ polyoxyethylene-polyoxypropylene block copolymer(Poloxamer[®], Pluronic[®] or Lutrol[®], BASF),
- ⑤ sodium dioctyl sulfosuccinate or sodium lauryl sulfate,
- ⑥ phospholipids,
- ⑦ trans-esterification products of natural vegetable oil triglycerides and polyalkylene polyols(Labrafil[®] M, Gattefosse) and Labrasol,
- ⑧ mono-, di- or mono/di-glycerides such as caprylic/capric acid mono- and

di-glycerides(Imwitor[®], Hüls), and

⑨ sorbitan fatty acid esters such as sorbitan monolauryl, sorbitan monopalmityl and sorbitan monostearyl esters(Span[®], ICI).

Among the above-mentioned surfactants, polyoxyethylene glycolated
5 hydrogenated vegetable oils, polyoxyethylene-polyoxypropylene block copolymer and polyoxyethylene-sorbitan-fatty acid esters are preferred.

(4) Oil

The oil may be any one of the pharmaceutically acceptable oils which is
10 compatible with the surfactant and stably emulsified in water to form a stable microemulsion. Representative examples of the oil include:

① fatty acid triglycerides, preferably medium chain fatty acid triglycerides, such as fractionated coconut oil(Miglyol[®] 812N, Hüls) and triacetin,

② mono-, di- or mono/di-glycerides, preferably mono- or di-glycerides of
15 oleic acid,

③ esters of fatty acids and monovalent alkanols, preferably esters of C₈₋₂₀ fatty acids and C₂₋₃ monovalent alkanols, such as isopropyl myristate, isopropyl palmitate, ethyl linoleate and ethyl oleate,

④ natural vegetable or animal oils such as corn oil, olive oil, soybean oil
20 and fish oil,

⑤ carbohydrates such as squalene and squalane,

⑥ tocopherols such as tocopherol or, tocopherol acetate, tocopherol succinate and polyethyleneglycol-1000-tocopherol succinate(TPGS), and

⑦ propyleneglycol mono- or di-fatty acid esters such as propyleneglycol
25 dicaprylate, propyleneglycol monocaprylate, propyleneglycol dilaurate, propyleneglycol isostearate, propyleneglycol monolaurate and propyleneglycol ricinolate etc.

Among the above-mentioned oils, esters of fatty acids and monovalent alkanols and propyleneglycol fatty acid esters are preferred.

30 In the preparation of the inventive microemulsion concentrate, the active

ingredient, the co-surfactant, the surfactant and the oil may be used in amounts corresponding to a weight ratio in the range of 1 : 0.5~20 : 0.5~10 : 0.04~1, preferably, 1 : 2~10 : 1~5 : 0.04~0.5. In the finally obtained microemulsion concentrate wherein the co-surfactant is removed, the weight ratio of the active
5 ingredient, the surfactant and the oil is in the range of 1 : 0.5~10 : 0.04~1, preferably, 1 : 1~5 : 0.04~0.5.

Emulsified drug microparticles contained in the microemulsion concentrate of the present invention are so stable against the pH change that the change of its emulsified state causing the precipitation of the active ingredient doesn't occur.
10 Upon contact with an aqueous solution, the inventive microemulsion concentrate may easily form a microemulsion containing emulsified drug microparticles having an average particle size ranging from 270 to 500 nm, preferably, from 300 to 400 nm. Accordingly, the microemulsion concentrate of the present invention is pharmaceutically very useful since it provides a remarkably improved bioavailability
15 of the drug when orally administered, and the drug bioavailability thereof is little influenced by pH change, thereby significantly decreasing the influences of the ingested food and individual absorption difference.

The microemulsion concentrate of the present invention may be formulated into soft or hard capsule, in accordance with any of the conventional
20 procedures. In addition, the inventive microemulsion concentrate may include pharmaceutically acceptable carriers, excipients or other additives for an oral administration, e.g., stabilizer, dissolution aid and anti-oxidants. Examples of the stabilizer include inorganic or organic acids (salts), preferably, phosphoric acid and anhydrous sodium acetate. The microemulsion concentrate may additionally
25 include diluents such as lactose, dextrose, sucrose, sorbitol, cellulose and glycin; lubricating agents such as silica, talc, stearic acids, magnesium or calcium salts of stearic acid, and polyethyleneglycol; coloring agents; flavoring agents; and sweetening agents.

The pharmaceutical formulation may be sterilized and/or additionally
30 include additives such as preservatives, stabilizers, wetting agents or emulsifying

promoters, osmotic agents such as salts and/or buffering agents; and other pharmacologically useful materials.

A typical daily dose of the anti-cold drug can be administered in a single dose or in divided doses.

5 The following Examples are intended to further illustrate the present invention without limiting its scope.

Example 1: Preparation of Microemulsion Concentrate and Soft Capsule

10 A soft capsule was prepared using the following ingredients:

	<u>Quantity(mg/capsule)</u>
Ibuprofen	200
(Ethanol)	(500)
Polyoxyethylene-40-hydrogenated castor oil	100
15 (Cremophor [®] RH40; BASF)	
Fluronic [®] L-44NF (BASF)	200
Tween [®] 20 (ICI)	200
Propyleneglycol monocaprylate (NIKKOL)	50

20 Ibuprofen (active ingredient) was uniformly dissolved in ethanol, and other ingredients were added thereto and dissolved to obtain a microemulsion pre-concentrate. Then, the resulting pre-concentrate was heated at 60 °C for 4 hours to remove ethanol and obtain a highly concentrated microemulsion concentrate wherein ibuprofen was completely dissolved. The microemulsion concentrate
25 was filled into a soft capsule in accordance with the conventional method described in the General Preparation Rule of the Korean Pharmacopoeia.

Example 2: Preparation of Microemulsion Concentrate and Soft Capsule

30 A soft capsule was prepared by the procedure of Example 1 using the

following ingredients:

	<u>Quantity(mg/capsule)</u>
Ibuprofen	200
(Ethanol)	(500)
5 Polyoxyethylene-40-hydrogenated castor oil	350
(Cremophor [®] RH40; BASF)	
Fluronic [®] L-44NF (BASF)	200
Propyleneglycol monocaprylate (NIKKOL)	50

10 Example 3: Preparation of Microemulsion Concentrate and Soft Capsule

A soft capsule was prepared by the procedure of Example 1 using the following ingredients:

	<u>Quantity(mg/capsule)</u>
15 Ibuprofen	200
(Ethanol)	(500)
Labrasol (GATTEFOSSE)	100
Tween [®] 20 (ICI)	250
Propyleneglycol monocaprylate (NIKKOL)	70

20

Example 4: Preparation of Microemulsion Concentrate and Soft Capsule

A soft capsule was prepared by the procedure of Example 1 using the following ingredients:

25

	<u>Quantity(mg/capsule)</u>
Ibuprofen	200
(Ethanol)	(500)
Polyoxyethylene-40-hydrogenated castor oil	350
30 (Cremophor [®] RH40; BASF)	

Tween [®] 20 (ICI)	200
Ethyl linolate (NIKKOL)	50

Example 5: Preparation of Microemulsion Concentrate and Soft Capsule

5

A soft capsule was prepared by the procedure of Example 1 using the following ingredients:

		<u>Quantity(mg/capsule)</u>
10	Ibuprofen	200
	(Ethanol)	(500)
	Labrasol [®] (GATTEFOSSE)	100
	Fluronic [®] L-44NF (BASF)	300
	Tween [®] 20 (ICI)	100
15	Propyleneglycol monocaprylate (NIKKOL)	50

Example 6: Preparation of Microemulsion Concentrate and Soft Capsule

20 A soft capsule was prepared by the procedure of Example 1 using the following ingredients:

		<u>Quantity(mg/capsule)</u>
	Ibuprofen	200
	(Ethanol)	(500)
25	Polyoxyethylene-40-hydrogenated castor oil	200
	(Cremophor [®] RH40; BASF)	
	Fluronic [®] L-44NF (BASF)	150
	Tween [®] 20 (ICI)	150
	Propyleneglycol monocaprylate (NIKKOL)	50

30

Example 7: Preparation of Microemulsion Concentrate and Hard Capsule

A hard capsule was prepared by the procedure of Example 1 using the following ingredients:

5

	<u>Quantity(mg/capsule)</u>
Acetaminophen	325
(Ethanol)	(1500)
Polyethyleneglycol 400	300
10 Tween [®] 20 (ICI)	40
Polyvinylpyrrolidone K-30	100
Anhydrous acetic acid	20
Triacetin	15

15 Example 8: Preparation of Microemulsion Concentrate and Hard Capsule

A hard capsule was prepared by the procedure of Example 1 using the following ingredients:

20

	<u>Quantity(mg/capsule)</u>
Acetaminophen	325
(Ethanol)	(1500)
Polyethyleneglycol 400	130
Labrasol [®] (GATTEFOSSE)	35
25 Polyvinylpyrrolidone K-30	230
Triacetin	35

Example 9: Preparation of Microemulsion Concentrate and Hard Capsule

30

A hard capsule was prepared by the procedure of Example 1 using the

following ingredients:

	<u>Quantity(mg/capsule)</u>
Acetaminophen	325
5 (Ethanol)	(1500)
Polyethyleneglycol 400	140
Labrasol® (GATTEFOSSE)	30
Polyvinylpyrrolidone K-30	225
Propyleneglycol monocaprylate (NIKKOL)	30

10

Example 10: Preparation of Microemulsion Concentrate and Hard Capsule

A hard capsule was prepared by the procedure of Example 1 using the following ingredients:

15

	<u>Quantity(mg/capsule)</u>
Acetaminophen	325
(Ethanol)	(1500)
Polyethyleneglycol 400	150
20 Fluronic® L-44NF (BASF)	30
Polyvinylpyrrolidone K-30	240
Triacetin	20

25

Example 11: Preparation of Microemulsion Concentrate and Soft Capsule

A soft capsule was prepared by the procedure of Example 1 using the following ingredients:

	<u>Quantity(mg/capsule)</u>
d-Chlorpheniramine maleate	2
30 Dextromethorphan hydrobromide	15

	Trimetoquinol hydrochloride	2
	Noscapine hydrochloride	20
	Guaifenesin	75
	(Ethanol)	(400)
5	Caprylic/Capric mono and di-glyceride	180
	(Capmul MCM)	
	Cremophor® RH40 (BASF)	220
	Ethyl linolate	20
	Miglyol® 812N (Hüls AM.)	30

10

Example 12: Preparation of Microemulsion Concentrate and Soft Capsule

A soft capsule was prepared by the procedure of Example 1 using the following ingredients:

15		<u>Quantity(mg/capsule)</u>
	d-Chlorpheniramine maleate	2
	Dextromethorphan hydrobromide	15
	Trimetoquinol hydrochloride	2
	Noscapine hydrochloride	20
20	Guaifenesin	75
	(Ethanol)	(400)
	Cremophor® RH40 (BASF)	250
	Labrasol® (GATTEFOSSE)	150
	Propyleneglycol monocaprylate (NIKKOL)	30

25

Example 13: Preparation of Microemulsion Concentrate and Soft Capsule

A soft capsule was prepared by the procedure of Example 1 using the following ingredients:

30	<u>Quantity(mg/capsule)</u>
----	-----------------------------

	d-Chlorpheniramine maleate	2
	Dextromethorphan hydrobromide	15
	Trimetoquinol hydrochloride	2
	Noscapine hydrochloride	20
5	Guaifenesin	75
	(Ethanol)	(400)
	Tween [®] 20 (ICI)	250
	Labrasol [®] (GATTEFOSSE)	150
	Propyleneglycol monocaprylate (NIKKOL)	30

10

Example 14: Preparation of Microemulsion Concentrate and Soft Capsule

A soft capsule was prepared by the procedure of Example 1 using the following ingredients:

15		<u>Quantity(mg/capsule)</u>
	d-Chlorpheniramine maleate	2
	Dextromethorphan hydrobromide	15
	Trimetoquinol hydrochloride	2
	Noscapine hydrochloride	20
20	Guaifenesin	75
	(Ethanol)	(400)
	Caprylic/Capric mono and di-glyceride	180
	(Capmul [®] MCM; Abitec)	
	Cremophor [®] RH40 (BASF)	220
25	Ethyl linolate	50

Test Example 1: Dissolution Test

The capsule prepared in Example 1 and the commercially available Brufen[®] tablet (Samil Pharm.) as a comparative preparation were subjected to a dissolution

30

test in accordance with the dissolution test method described in Korea pharmacopoeia (the paddle method). Aliquots of each solution were taken at regular intervals and filtered through a 1 μm membrane filter. The amounts of ibuprofen dissolved therein were determined using the following method:

5

- Test apparatus: Erweka DT 80
- Test solutions: 900 ml each of artificial gastric juice (pH 1.2) and water (pH 6.8)
- Temperature of test solutions: $37 \pm 0.5^\circ\text{C}$
- Rotation speed: 50 ± 2 rpm
- Sampling time: 5, 10, 15, 30, 45 and 60 min.
- Analysis method: liquid chromatography
 - Column: Inertsil ODS2 (150 mm \times 4.6 mm)
 - Mobile phase: acetonitrile : 1% chloroacetate (pH 3.0) (65:35 v/v)
 - Injection volume: 20 μl
 - Flow rate: 1.0 ml/min.
 - Detector: UV 254 nm

10

15

The time-dependent changes in the amount of dissolved ibuprofen are shown in Figs. 1a and 1b (Fig. 1a: artificial gastric juice, Fig. 1b: water).

20

As shown in Figs. 1a and 1b, the microemulsion concentrate of Example 1 exhibited higher dissolution rates than the comparative preparation in both test solutions, without the precipitation of the active ingredient due to the pH change.

25 Test Example 2: Analysis of the emulsified drug microparticles

In order to examine whether the preparation of Example 1 is spontaneously emulsified to microparticles upon contact with an aqueous solution, a particle size distribution analysis was carried out, as follows.

30

0.1g of the test preparation was diluted with 10 ml of distilled water, and

then, the particle size distribution was determined with a particle analyzer (Shimadzu, SALD-2002 model, Japan). The result is shown in Fig. 2.

As shown in Fig. 2, the inventive microemulsion concentrate formed an emulsified drug microparticles having an average particle size ranging from about
5 270 to 500 nm upon contact with an aqueous solution, thereby forming a microemulsion easily.

Test Example 3: Precipitation Formation Test

10 In order to examine whether the preparation of Example 1 forms precipitations upon contact with an aqueous solution, each 0.1g of the preparation of Example 1 and the comparative preparation (Brufen[®] tab.; Samil Pharm.) were diluted to 10 ml of distilled water, artificial gastric juice and artificial intestinal juice, respectively, and then, formation of precipitation was observed with eyes
15 immediately.

The artificial gastric juice was prepared by adding 2g of NaCl and 7 ml of HCl to 900 ml of water to have pH 1.2 and adjusting total volume of the solution to 1 l by adding water thereto. The artificial intestinal juice was prepared by mixing 250 ml of 0.2 mol/L KH_2PO_4 and 118 ml of 0.2 mol/L
20 NaOH and adjusting pH to 6.8 and adding water thereto to a total volume of 1 l. The result of the precipitation formation test is shown in Table 1.

<Table 1>

	Distilled water	Artificial gastric juice	Artificial intestinal juice
Example 1	-	-	-

(small precipitation: +, large precipitation: ++, no precipitation: -)

25

As shown in Table 1, the inventive microemulsion preparation does not form precipitations upon contact with an aqueous solution, therefore the desired absorption rate and bioavailability improvement can be achieved.

Test Example 4: Absorption Test

In order to investigate the bioavailability of the drug contained in the
5 inventive preparation, in vivo absorption test was carried out as follows by
employing the preparation of Example 1 (Experimental preparation) and the
commercially available preparation (Brufen®; Samil Pharm.) as a comparative
preparation.

Six 14 to 15-week old male Sprague-Dawley rats (weight: 250g) were
10 acclimated for more than 4 days with allowing free access to the feed and water.
And then, the rats were put on a fast over 48-hours, while they were allowed to
free access to water.

The rats were divided into two groups each consisting of three rats, and
the rats were orally administered with the experimental or comparative
15 preparation in an amount corresponding to 20 mg/kg of ibuprofen. Blood
samples were taken from the rats before administration, and 15, 30, 45 and 60 min.
and 2, 3, 4 and 6 hours after the administration, respectively. 200 μl of inner
standard solution (10 $\mu\text{g}/\text{ml}$ propylparaben in methanol) and 200 μl of
methanol were added to 200 μl of plasma, and the mixture was shaken. The
20 mixture was centrifuged at 3,000 rpm for 10 minutes to obtain a supernant, which
was then filtered with a 0.22 μm filter and analyzed by HPLC, as follows.

- Column: Inertsil ODS2 (4.6 mm \times 250 mm, 5 μm)
- Mobile phase: 65% acetonitrile solution containing 0.1M sodium acetate
- 25 - Injection volume: 20 μl
- Flow rate: 1.0 ml/min.
- Detector: 222 nm

The results is shown in Table 2 and Fig. 3.

<Table 2>

Preparation	AUC (ng·hr/ml)	C _{max} (ng/ml)	T _{max} (hour)
Brufen [®] tablet (Samil Pharm.)	2017.7±241.4	22.4±2.4	15.0±0.0
Example 1	2878.4±1300.1	34.2±17.6	22.5±6.1
AUC: Area under the plasma concentration versus time curve till 24 hours			
C _{max} : Maximum blood concentration			
T _{max} : Time at the maximum blood concentration			

As shown in Table 2 and Fig. 3, the bioavailability of the inventive preparation of Example 1 was improved than Brufen[®] tablet.

5 In considering the fact that, as shown in Figs. 1a and 1b, the inventive microemulsion preparation exhibits a more stable dissolution rate against the pH change than the comparative preparation, can be suggested that the inventive microemulsion concentrate can form stable emulsified drug microparticles upon contact with a body fluid, thereby maintaining the bioavailability constantly
10 without the change of the emulsified state depending on pH, such as precipitation of the drug.

While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may
15 be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.


WHAT IS CLAIMED IS:

1. A method for preparing a microemulsion concentrate for oral administration of a water-insoluble anti-cold drug comprising (a) dissolving the water-insoluble anti-cold drug in a co-surfactant to obtain a homogeneous drug solution; (b) adding a surfactant and an oil in the drug solution to obtain a microemulsion pre-concentrate; and (c) removing the co-surfactant from the pre-concentrate.
2. The method of claim 1, wherein the water-insoluble anti-cold drug is selected from the group consisting of acetaminophen, ibuprofen, S-ibuprofen, dextromethorphan hydrobromide, noscapine hydrochloride, trimetoquinol hydrochloride, guaifenesin, d-chlorpheniramine maleate, carbetapentane citrate, tipecidine citrate, cloperastine hydrochloride, cloperastine fendizoate, tipecidine hibenzate, d,l-methylephedrine hydrochloride, ephedrine hydrochloride, phenylephedrine hydrochloride, pseudoephedrine hydrochloride, phenylpropanolamine and a mixture thereof.
3. The method of claim 1, wherein the co-surfactant is an organic solvent having a boiling point lower than 100°C.
4. The method of claim 3, wherein the co-surfactant is ethanol.
5. The method of claim 1, wherein the surfactant is selected from the group consisting of polyoxyethylene hydrogenated vegetable oils, polyoxyethylene-polyoxypropylene block copolymer, polyoxyethylene-sorbitan-fatty acid esters, polyoxyethylene fatty acid esters, sodium dioctyl sulfosuccinate or sodium lauryl sulfate, phospholipids, trans-esterification products of natural vegetable oil triglycerides and polyalkylene polyols, mono/di-glycerides, sorbitan fatty acid esters and a mixture thereof.


6. The method of claim 1, wherein the oil is selected from the group consisting of esters of fatty acids and monovalent alkanols, propyleneglycol mono- or di-fatty acid esters, fatty acid triglycerides, mono/di-glycerides, natural vegetable
5 or animal oils, carbohydrates, tocopherols and a mixture thereof.
7. The method of claim 1, wherein the water-insoluble anti-cold drug : co-surfactant : surfactant : oil ratio by weight is in the range of 1 : 0.5~20 : 0.5~10 : 0.04~1.
10
8. The method of claim 1, wherein the co-surfactant is removed in step (C) by heating the pre-concentrate at a temperature ranging from 50 to 100°C.
9. A microemulsion concentrate prepared by the method of claim 1
15 comprising a water-insoluble anti-cold drug, a surfactant and an oil.
10. The microemulsion concentrate of claim 9, wherein the water-insoluble anti-cold drug : surfactant : oil ratio by weight is in the range of 1 : 0.5~10 : 0.04~1.
- 20 11. The microemulsion concentrate of claim 9, which forms microparticles having an average particle size ranging from 270 to 500 nm upon contact with an aqueous solution.

1/4

FIG. 1a




2/4
FIG. 1b




3/4

FIG. 2





4/4

FIG. 3



INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR03/02388

A. CLASSIFICATION OF SUBJECT MATTER IPC7 A61K 9/107 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC7 A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched KOREAN PATENTS AND APPLICATIONS FOR INVENTIONS SINCE 1975 Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS(STN), WPI, USPATFULL, JAPIO		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02/058480 A1 (UNILEVER N.V.; UNILEVER PLC; HINDUSTAN LEVER LTD.) 1 AUGUST 2002 see the whole document	1
A	US 4388307 A (SANDOZ LTD.) 14 JUNE 1983 see the whole document	1
A	US 6190646 B1 (ELF AQUITAINE) 20 FEBRUARY 2001 see the whole document	1
A	WO 99/39700 A1 (VECTORPHARMA S.P.A.) 12 AUGUST 1999 see the whole document	1
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search 29 DECEMBER 2003 (29.12.2003)		Date of mailing of the international search report 30 DECEMBER 2003 (30.12.2003)
Name and mailing address of the ISA/KR  Korean Intellectual Property Office 920 Dunsan-dong, Seo-gu, Daejeon 302-701, Republic of Korea Facsimile No. 82-42-472-7140		Authorized officer YOO, JUN SEOK Telephone No. 82-42-481-8163 

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR03/02388

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
W002058480A1	01.08.2002	CA2432998AA	01.08.2002
		EP1353564A1	22.10.2003
		US20020098275A1	25.07.2002
US4388307A	14.06.1983	AR223667A1	15.09.1981
		AT163779A	15.02.1984
		AU4486279A	13.09.1979
		CA1139667A1	18.01.1983
		CY1285A	05.07.1985
		DD142149A5	11.06.1980
		DE2907460A1	13.09.1979
		DK86079A	08.09.1979
		ES478295A1	16.05.1979
		FI790640A	08.09.1979
		FR2419072A1	05.10.1979
		GB2015339A	12.09.1979
		HK48585A	28.06.1985
		IE48016B1	05.09.1984
		IL56790A	31.01.1982
		IT1115038B	03.02.1986
		JP54132223A	15.10.1979
		KE3516A	19.04.1985
		MY13485A	31.12.1985
		NL7901703A	11.09.1979
		N0790661A	10.09.1979
		NZ189819A	31.05.1984
		PH15159A	24.08.1982
		PT69309A	01.04.1979
		SE7901683A	08.09.1979
		SG14785G	16.08.1985
US6190646B1	20.02.2001	BR0006900A	12.06.2001
		EP1113863A1	11.07.2001
		FR2795974A1	12.01.2001
		N020011046A	03.05.2001
		W00102086A1	11.01.2001
W09939700A1	12.08.1999	AU2723899A	23.08.1999
		BR9907683A	14.11.2000
		CA2319565A1	12.08.1999
		EP1051160A1	15.11.2000
		ITM1980234A1	06.08.1999
		JP2002502813T	29.01.2002